David Ketteridge

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 216 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human <i>N</i>-Acetylgalactosamine 4-Sulfatase

Paul Harmatz, David Ketteridge, Roberto Giugliani et al. · PEDIATRICS · 2005 · 215 citations

Life Sciences, Biochemistry, Clinical Biochemistry +16

Clinical presentation and outcome in a series of 88 patients with the cblC defect

Sabine Fischer, Martina Huemer, Matthias R. Baumgartner et al. · Journal of Inherited Metabolic Disease · 2014 · 169 citations · Full text

Medicine, Radiology, Diagnostic Pathology +1

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Stuart J. Swiedler, Michael Beck, M Bajbouj et al. · American Journal of Medical Genetics Part A · 2005 · 162 citations

Medicine, Neurology, Molecular Pathology +12

Mutational analysis of 105 mucopolysaccharidosis type VI patients

Litsa Karageorgos, Doug A. Brooks, A.C. Pollard et al. · Human Mutation · 2007 · 138 citations

Life Sciences, Genetics, Molecular Genetics +16